(2R,4S)-4-fluoropyrrolidine-1,2-dicarboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,4S)-4-fluoropyrrolidine-1,2-dicarboxylic acid
• 化学式: C₆H₈FNO₄
• 分子量: 177.13
• InChiKey: GXFAYZBQUMULJS-IUYQGCFVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER<br/>[FR] COMPOSÉS DE 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO [4,3-C]PYRIMIDIN-3-ONE DESTINÉS À ÊTRE UTILISÉS CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2021191378A1

  公开（公告）日：2021-09-30

  Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

  本文描述了式（I）的三唑酮化合物及其药用盐。还描述了制备和使用式（I）化合物的方法。式（I）的化合物及其药用盐可用作腺苷受体拮抗剂，例如在治疗由腺苷受体介导的疾病或症状，如癌症、运动障碍或注意力障碍方面。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：EP3406609A1

  公开（公告）日：2018-11-28

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1b or a salt thereof, wherein Q, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括符合式 1b 的化合物 或其盐，其中 Q、R3 和 R4 如本文所定义。
• EP300/CREBBP INHIBITOR
  申请人：Daiichi Sankyo Co., Ltd.

  公开号：EP3643703A1

  公开（公告）日：2020-04-29

  The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

  本发明提供了一种对 EP300 和/或 CREBBP 具有优异组蛋白乙酰转移酶抑制活性的化合物或其药理学上可接受的盐。该化合物由下式（1）或其药理学上可接受的盐表示： 其中，环 Q1、环 Q2、R1、R2、R3 和 R4 分别具有本说明书中定义的相同含义。
• Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10011612B2

  公开（公告）日：2018-07-03

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供了包含式 I 或其药学上可接受的盐或组合物的补体因子 D 抑制剂的化合物、使用方法和制造工艺，其中 A 基上的 R12 或 R13 是芳基、杂芳基或杂环 (R32)。本文所述的因子 D 抑制剂可减少补体的过度活化。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.
  申请人：Heptares Therapeutics Limited

  公开号：EP3102568B1

  公开（公告）日：2018-06-27